Pharmacotherapy of primary obsessive-compulsive disorder: Review of the literature

Pharmacotherapy

Volumn 18, Issue 5, 1998, Pages 936-960

  Ellingrod, Vicki L ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; BUSPIRONE; CLOMIPRAMINE; CLONAZEPAM; CLONIDINE; CLORGYLINE; DESIPRAMINE; DIPHENHYDRAMINE; FENFLURAMINE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; LITHIUM; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRYPTOPHAN;

ANTICHOLINERGIC EFFECT; CLINICAL FEATURE; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; GASTROINTESTINAL TOXICITY; HUMAN; MAINTENANCE THERAPY; NEUROLOGIC DISEASE; OBSESSION; PATHOPHYSIOLOGY; PATIENT COUNSELING; PSYCHOTHERAPY; RATING SCALE; RELAXATION TRAINING; REVIEW; SIDE EFFECT;

CLINICAL TRIALS; CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; SEROTONIN UPTAKE INHIBITORS;

EID: 0031656031     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (98)

1. Karno M, Golding JM, Sorenson SB, Burnam MA. The epidemiology of obsessive-compulsive disorder in five U.S. communities. Arch Gen Psychiatry 1988;45:1094-9.
2. McDougle CJ, Goodman WK, Leckman JF, Price LH. The psychopharmacology of obsessive compulsive disorder. Psychiatr Clin North Am 1993;16:749-65.
3. Weissman MM, Bland RC, Canino GJ, et al. The cross national epidemiology of obsessive compulsive disorder. J Clin Psychiatry 1994;55(suppl 3):5-10.
4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: Author, 1994.
5. Rasmussen SA, Eisen JL. The epidemiology and clinical features of obsessive compulsive disorder. Psychiatr Clin North Am 1992;15:743-58.
6. Rapoport JL. The neurobiology of obsessive-compulsive disorder. JAMA 1988;260:2888-90.
7. Koblenzer CS. Cutaneous manifestations of psychiatric disease that commonly present to the dermatologist - diagnosis and treatment. Int J Psychiatry Med 1992;22:47-63.
8. Expert Consensus Panel for Obsessive-Compulsive Disorder. Treatment of obsessive-compulsive disorder. J Clin Psychiatry 1997;58(suppl 4):1-72.
9. Black DW, Noyes R Jr, Pfohl B, Goldstein RB, Blum N. Personality disorder in the obsessive-compulsive volunteers, well comparison subjects, and their first degree relatives. Am J Psychiatry 1993;150:1226-32.
10. Chouinard G. Sertraline in the treatment of obsessive compulsive disorder: two double-blind, placebo-controlled studies. Int Clin Psychopharmacol 1992;7(suppl 2):37-41.
11. Trivedi MH. Functional neuroanatomy of obsessive-compulsive disorder. J Clin Psychiatry 1996;57(suppl 8):26-36.
12. Goodman W, Price L, Rasmussen S, et al. The Yale-Brown obsessive-compulsive scale. II. Validity. Arch Gen Psychiatry 1989;46:1012-16.
13. Black DW. Obsessive-compulsive disorder and its relationship to other disorders. Resident Staff Physician 1997;43:64-76.
14. National Institute of Mental Health. Special feature: rating scales and assessment instruments for use in pediatric psychopharmacology research. Psychopharmacol Bull 1985;21(4):714-1124.
15. Asberg M, Montgomery S, Perris C, Schalling D, Sedvall G. A comprehensive psychopathological rating scale. Acta Psychiatr Scand 1978;suppl 271:5-27.
16. Hodgson RJ, Rachman S. Obsessional-compulsive complaints. Behav Res Ther 1977;15:389-95.
17. Cooper J. The Leyton obsessional inventory. Psychol Med 1970;l:48-64.
18. Guy W. ECDEU assessment manual for psychopharmacology. Washington, DC: U.S. Department of Health and Education and Welfare, 1976:218-22.
19. Hamilton M. A rating score for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
20. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9.
21. Rapoport J, Elkins R, Mikkelson E. Clinical controlled trial of clomipramine in adolescents with obsessive-compulsive disorder. Psychopharmacol Bull 1980;16:61-3.
22. Allen JJ, Tune GS. The Lynfield obsessional/compulsive questionnaire. Scott Med J 1975;20:21-4.
23. Mavissakalian M, Turner SM, Michelson L, Jacob R. Tricyclic antidepressants in obsessive-compulsive disorder: antiobsessional or antidepressive agents? II. Am J Psychiatry 1985;142:572-6.
24. Marks IM, Stern RS, Mawson D, Cobb J, McDonald J. Clomipramine and exposure for obsessive-compulsive rituals. I. Br J Psychiatry 1980;136:1-25.
25. Snaith RP, Ahmed SN, Mehta S, Hamilton M. Assessment of the severity of primary depressive illness. Wakefield self-assessment depression inventory. Psychol Med 1971;1:143-9.
26. Gelder MG, Marks IM. Severe agoraphobia: a controlled prospective trial of behaviour therapy. Br J Psychiatry 1966;112:309-19.
27. Flament MF, Rapoport JL, Berg CJ, et al. Clomipramine treatment of childhood obsessive-compulsive disorder: a double-blind controlled study. Arch Gen Psychiatry 1985;42:977-83.
28. Berg CJ, Rapoport JL, Filament MF. The Leyton obsessional inventory-child version. J Am Acad Child Psychiatry 1986;25:94-1.
29. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962;10:799-812.
30. Marks IM, Lelliott P, Basoglu M, et al. Clomipramine, self-exposure and therapist-aided exposure for obsessive-compulsive rituals. Br J Psychiatry 1988;152:522-34.
31. Mavissakalian MR, Jones B, Olson S, Perel JM. Clomipramine in obsessive-compulsive disorder: clinical response and plasma levels. J Clin Psychopharmacol 1990;10:261-8.
32. Zung WWK. A rating instrument for anxiety disorders. Psychosomatics 1971;12:371-9.
33. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;50:53-63.
34. Jenike MA, Baer L, Summergrad P, Weilburg JB, Holland A, Seymour R. Obsessive-compulsive disorder: a double-blind, placebo-controlled trial of clomipramine in 27 patients. Am J Psychiatry 1989;146:1328-30.
35. Clomipramine Collaborative Study Group. Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 1991;48:730-8.
36. DeVeaugh-Geiss J, Moroz G, Biederman J, et al. Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder - a multicenter trial. J Am Acad Child Adolesc Psychiatry 1992;31:45-9.
37. Thorn P, Asberg M, Cronholm B, Jornestedt L, Traskman L. Clomipramine treatment of obsessive-compulsive disorder: a controlled clinical trial. Arch Gen Psychiatry 1980;37:1281-5.
38. Ananth J, Pecknold JC, VanDen Steen N, Engelsmann F. Double-blind comparative study of clomipramine and amitriptyline in obsessive neurosis. Prog Neuropsychopharmacol 1981;5:257-62.
39. Wyndowe J, Solymon L, Ananth J. Anafranil in obsessive compulsive neurosis. Curr Ther Res 1977;18:611-17.
40. Insel TR, Murphy DL, Cohen RM, Alterman I, Kilts C, Linnoila M. Obsessive-compulsive disorder: a double-blind trial of clomipramine and clorgyline. Arch Gen Psychiatry 1983;40:605-12.
41. Volavka J, Neziroglu F, Yaryura-Tobias JA. Clomipramine and imipramine in obsessive-compulsive disorder. Psychiatry Res 1985;14:83-91.
42. Cammer L. Freedom from compulsion. New York: Simon & Schuster, 1977:108.
43. Zohar J, Insel TR. Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment and pathophysiology. Biol Psychiatry 1987;22:667-87.
44. Leonard H, Swedo S, Rapoport JL, Coffey M, Cheslow D. Treatment of childhood obsessive compulsive disorder with clomipramine and desmethylimipramine: a double-blind crossover comparison. Psychopharmacol Bull 1988;24:93-5.
45. Leonard HL, Swedo SE, Rapoport JL, et al. Treatment of obsessive-compulsive disorder with clomipramine and desipramine in children and adolescents: a double-blind crossover comparison. Arch Gen Psychiatry 1989;46:1088-92.
46. Pigott TA, Pato MT, Berstein SE, et al. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1990;47:926-32.
47. Lopez-Ibor JJ, Saiz J, Cottraux J, et al. Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder. Eur Neuropsychopharmaol 1996;6:111-18.
48. Pato MT, Pigott TA, Hill JL, Grove GN, Bernstein S, Murphy DL. Controlled comparison of buspirone and clomipramine in obsessive-compulsive disorder. Am J Psychiatry 1991;148:127-9.
49. Vallejo J, Olivares J, Marcos T, Bullpen A, Menchon JM. Clomipramine versus phenelzine in obsessive-compulsive disorder: a controlled clinical trial. Br J Psychiatry 1992;161:665-70.
50. Philpott R. Recent advances in the behavioral measurement of obsessional illness: difficulties common to these and other measures. Scot Med J 1975;20:33-9.
51. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-5.
52. Hewlett WA, Vinogradov S, Agras S. Clomipramine, clonazepam, and clonidine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 1992;12:420-30.
53. Freeman CPL, Timble MR, Deakin JFW, Strokes TM, Ashford JJ. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison. J Clin Psychiatry 1994;55:301-5.
54. Koran LM, McLeroy SL, Davison JRT, Rasmussen SA, Hollander E, Jenike MA. Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double blind comparison. J Clin Psychopharmacol 1996;16:121-9.
55. Zohar J, Judge R. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. Br J Psychiatry 1996;169:468-74.
56. Parloff MB, Kelman HC, Frank JD. Comfort, effectiveness and self-awareness as criteria of improvement in psychotherapy. Am J Psychiatry 1954;111:343-51.
57. Bisserbe JC, Lane RM, Filament MF, et al. A double-blind comparison of sertraline and clomipramine in outpatients with obsessive-compulsive disorder. Eur Psychiatry 1997;12:82-93.
58. Riddle MA, Scahill L, King RA, et al. Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 1992;31:1062-9.
59. Scahill L, Riddle MA, McSwiggin-Hardin M, et al. Children's Yale-Brown Obsessive Compulsive Scale: reliability and validity. J Am Acad Child Adolesc Psychiatry 1997;36:844-52.
60. Leckman JF, Towbin KE, Ort SI, Cohen DJ. Clinical assessment of tic disorder severity. In: Cohen DJ, Brunn R, Leckman JF, eds. Tourette syndrome and tic disorders: clinical understanding and treatment. New York: Wiley, 1988:55-78.
61. Shaffer D, Gould MS, Brasic J, et al. A children's global assessment scale (CGAS). Arch Gen Psychiatry 1983;4:53-63.
62. Reynolds CD, Richmond B. Revised children's manifest anxiety scale (RCMAS) manual. Los Angeles: Western Psychological Services, 1987.
63. Kovacs M. The children's depression inventory (CDI). Psychopharmacology 1985;21:995-1000.
64. Montgomery SA, McIntyre A, Osterheider M, et al. A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. Eur Neuropsychopharmacol 1993;3:143-52.
65. Covi L, Lipman RS, McNair DM, Czerlinsky T. Symptomatic volunteers in multicentre drug trials. Prog Neuropsychopharmacol 1979;3:521-33.
66. Tollefson GD, Rampey AH, Potvin JH, et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1994;51:559-67.
67. Perse TL, Greist JH, Jefferson JW, Rosenfeld R, Dar R. Fluvoxamine treatment of obsessive-compulsive disorder. Am J Psychiatry 1987;144:1543-8.
68. Rachman SJ, Hodgson RJ. Obsessions and compulsions. Englewood Cliffs, NJ: Prentice-Hall, 1980.
69. Goodman WK, Price LJ, Rasmussen SA, Delgado PL, Heninger GR, Charney DS. Efficacy of fluvoxamine in obsessive-compulsive disorder: a double-blind comparison with placebo. Arch Gen Psychiatry 1989;46:36-44.
70. Cottraux J, Mollard E, Bouvard M, et al. A controlled study of fluvoxamine and exposure in obsessive-compulsive disorder. Int Clin Psychopharmacol 1990;5:17-30.
71. Jenike MA, Baer L, Summergrad P, Minichiello WE, Holland A, Seymour R. Sertraline in obsessive-compulsive disorder: a double-blind comparison with placebo. Am J Psychiatry 1990;147:923-8.
72. Goodman WK, Kozak MJ, Liebowitz M, White KL. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial. Int Clin Psychopharmacol 1996;11:21-9.
73. Goodman WK, Price LH, Delgado PL, et al. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1990;47:577-85.
74. Wheadon DE, Bushnell W, Steiner M. A fixed dose comparison of 20, 40, or 60 mg paroxetine to placebo in the treatment of obsessive-compulsive disorder [abstr]. Presented at the meeting of the American College of Neuropharmacology, San Juan, Puerto Rico, December, 1993.
75. Chiounard G, Goodman W, Greist J, et al. Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder. Psychopharmacol Bull 1990;26(3):279-84.
76. Jenike MA, Baer L, Summergrad P, Minichiello WE, Holland A, Seymour R. Sertraline in obsessive-compulsive disorder: a double-blind comparison with placebo. Am J Psychiatry 1990;147:923-8.
77. Griest J, Chouinard G, DuBoff E, et al. Double-blind comparison of three doses of sertraline and placebo in outpatients with obsessive compulsive disorder. Arch Gen Psychiatry 1995;52:289-95.
78. Prasad A. A double blind study of imipramine versus zimelidine in treatment of obsessive compulsive neurosis. Pharmacopsychiatry 1984;17:61-2.
79. Foa EB, Steketee G, Kozak MJ, Dugger D. Imipramine and placebo in the treatment of obsessive-compulsives: the effect on depression and on obsessional symptoms. Psychopharmacol Bull 1987;23:8-11.
80. Pigott TA, L'Heureux F, Rubenstein CS, Bernstein SE, Hill JL, Murphy DL. A double-blind, placebo controlled study of trazodone in patients with obsessive-compulsive disorder. J Clin Psychopharmacol 1992;12:156-62.
81. Ravizza L, Barzega G, Bellilno S, Bogetto F, Maina G. Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs). Psychopharmacol Bull 1996;32:167-73.
82. Mundo E, Bareggi SR, Pirola R, Bellodi L, Smeraldi E. Long-term pharmacotherapy of obsessive-compulsive disorder: a double-blind controlled study. J Clin Psychopharmacol 1997;17:4-10.
83. McDougle CJ. Update on pharmacologic management of OCD: agents and augmentation. J Clin Psychiatry 1997;58(suppl 12):11-17.
84. Jenike MA, Hyman S, Baer L, et al. A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory. Am J Psychiatry 1990;147:1209-14.
85. Rassmussen SA. Lithium and tryptophan augmentation in clomipramine resistant obsessive-compulsive disorder. Am J Psychiatry 1987;141:1283-5.
86. Mattes J. A pilot study of combined trazodone and tryptophan in obsessive-compulsive disorder. Int Clin Psychopharmacol 1986;1:170-3.
87. Hollander E, DeCaria CM, Schneier FR, et al. Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment. J Clin Psychiatry 1990;51:119-23.
88. McDougle CJ, Goodman WK, Price LH, et al. Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry 1990;147:652-4.
89. McDougle CJ, Goodman WK, Leckman JF, et al. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: a double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 1994;51:302-8.
90. Stein DJ, Bouwer C, Hawkridge S, Emsley RA. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. J Clin Psychiatry 1997; 58:119-22.
91. Cardinale V. 1996 drug topics red book. Montvale, NJ: Medical Economics, 1996.
92. Piccinelli M, Pini S, Bellantuono C, Wilkinson G. Efficacy of drug treatment in obsessive-compulsive disorder. a meta-analytic review. Br J Psychiatry 1995;166:424-43.
93. Ananth J, Burgoyne K, Smith M, Swartz R. Venlafaxine for treatment of obsessive-compulsive disorder [letter]. Am J Psychiatry 1995;152:1832.
94. Grossman R, Hollander E. Treatment of obsessive-compulsive disorder with venlafaxine [letter]. Am J Psychiatry 1996;153:567-77.
95. Nelson EC. An open-label study of nefazodone in the treatment of depression with and without comorbid obsessive-compulsive disorder. Ann Clin Psychiatry 1994;6:249-53.
96. Yaryura-Tobias JA, Nezirogula FA. Venlafaxine in obsessive-compulsive disorder [letter]. Arch Gen Psychiatry 1996; 53:653-4.
97. Rauch SL, O'Sullivan RL, Jenike MA. Open treatment of obsessive-compulsive disorder with venlafaxine: a series of ten cases [letter]. J Clin Psychopharmacol 1996;16:81-4.
98. Goodman WK, Price LH. Assessment of severity and change in obsessive compulsive disorder. Psychiatr Clin North Am 1992;15:861-9.